Psychedelic Therapy is the Future

The historical background of psychedelics traces back to prehistoric times. However, in the 1950s and early 1960s, medical researchers in America began recognizing the therapeutic properties of psilocybin and other psychedelics in mental health and behavioral disorders. Harvard University spearheaded the surge in research on the positive uses of psychedelics during the early 1960s. Initial research outcomes showed promising results, with reduced recidivism rates among incarcerated individuals who underwent psilocybin therapy and a significant number of participants reporting positive life changes post-treatment*. These findings underscored the potential of psychedelics to improve mental health outcomes and prompted further exploration into its therapeutic benefits and consciousness-expanding properties.

Psychedelic substances faced significant scrutiny and opposition in the US during the turbulent era of the late 1960s and early 1970s. The demonization of psychedelics, fueled by political agendas and societal fears, led to a halt in academic research and therapeutic exploration.

However, the last two decades we have witnessed a resurgence in interest and research regarding the potential therapeutic benefits of psychedelics, including psilocybin, THC, MDMA and Ketamine. The field of psychedelic-assisted therapy is undergoing a renaissance, with a growing body of evidence supporting the efficacy of these substances in addressing mental health challenges, with positive results, as reported decades earlier.

The legalization of substances like MDMA and psilocybin is a topic of ongoing debate and delayed progress. As research continues to evolve and regulations shift, it is important to note that Ketamine currently stands as the only psychedelic considered safe and legal for therapeutic use within every state in the United States.

* The Concord Prison Experiment 1961-1963